Last reviewed · How we verify
Vi-DT Vaccine
At a glance
| Generic name | Vi-DT Vaccine |
|---|---|
| Also known as | Typhoid Conjugate Vaccine |
| Sponsor | PT Bio Farma |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV
- Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian (PHASE2, PHASE3)
- Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh (PHASE1, PHASE2)
- Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III) (PHASE3)
- Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) (PHASE3)
- Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine (PHASE2)
- Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine (PHASE1)
- Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vi-DT Vaccine CI brief — competitive landscape report
- Vi-DT Vaccine updates RSS · CI watch RSS
- PT Bio Farma portfolio CI